SYBX Rasio cepet Synlogic Inc.

Synlogic, Inc. (SYBX) is implementing advanced microbiome programming methods, creating unique therapeutic agents based on modified bacteria. The share price history with the 2.74 metric reflects the dynamics of a synthetic biotic pioneer whose engineering platform enables the detoxification of the body in cases of rare pathologies. Currently, the business relies on targeted license sales amid a profound transformation of the metabolic therapy niche.

Logistics optimization of biologics and hub control at Synlogic, Inc. (SYBX) directly impact current quick liquidity, reflecting the company's ability to promptly fund its obligations. This indicator measures the ratio of cash and accounts receivable excluding inventory, allowing investors to assess real solvency and capital stability without depending on the sale of remaining stock.